Cambridge Antibody Technology Gains Access to Incyte LifeSeq® Gold Database and Options to Develop and Commercialize Human Therapeutic Antibody Products Palo Alto, CA, and Melbourn, England, December 19, 2001—Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company, and Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT), today announce an agreement which gives CAT access to the Incyte LifeSeq® Gold database and options for product development rights. Under the terms of the agreement, CAT will receive access to Incyte's LifeSeq® Gold database and to high quality, sequence verified human cDNA clones and rights to use this information for therapeutic antibody product development. In addition, CAT will have the ability to take several exclusive licences under Incyte antibody patent rights to discover, develop and commercialize therapeutic antibodies with specificity for target proteins in the database. CAT will pay a licence fee, plus milestones and royalties in relation to therapeutic human antibody products developed. "We're excited by the alliance with Cambridge Antibody Technology," said Paul A. Friedman, MD, Chief Executive Officer of Incyte. "CAT has developed an advanced antibody technology platform and is experienced in the development of therapeutic human antibody products. In addition, this alliance demonstrates our continued commitment to leverage our position as the leader of genomic information and reaffirms the value of LifeSeq Gold for human antibody therapeutic companies such as CAT." "Dr. David Chiswell, CAT's Chief Executive Officer, commented "This alliance with Incyte presents CAT with a further opportunity to deliver antibody-based drugs to genomics targets. CAT is very pleased to obtain patent rights from Incyte to research, develop and commercialize antibody-based drugs. CAT has already demonstrated the power of combining antibody phage display and genomics-based target discovery, and this agreement adds a significant new source of genomics-derived targets to fuel CAT's drug development pipeline." About Incyte Genomics: Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com. About Cambridge Antibody Technology (CAT): CAT is a UK biotechnology company using its proprietary technologies in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 250 people. CAT is listed on the London Stock Exchange and on NASDAQ since June 2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering in March 2000. CAT has an advanced platform technology for rapidly isolating human monoclonal antibodies using phage display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs and to utilize antibodies as tools for target validation. Six human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT has alliances with a large number of biotechnology and pharmaceutical companies to discover develop and commercialize human monoclonal antibody-based products. CAT has also licensed its proprietary human antibody phage display libraries to several companies for target validation and drug discovery. CAT's collaborators include: Abbott, Elan, Eli Lilly, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Merck & Co., Inc., Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst, Xerion and Zyomyx. For Incyte: Except for the historical information contained herein, the matters set forth in this press release including, without limitation, statements as to the potential success of the parties in advancing the development of therapeutic antibody products, Incyte's position as a leader in genomic information, the ability of the agreement to assist and potentially accelerate CAT's therapeutic discovery efforts, the revenue-generating impact that the agreement will have for both companies, the ability of Incyte's products and services to enhance the research efforts of, and provide value to, its customers, and Incyte's ability to leverage its intellectual property position to become a leader in therapeutic discoveries are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the extent to which the parties will succeed in identifying and commercializing therapeutic antibodies; the ability of the parties to provide products and services that meet market needs and that beat other substantially similar products and services to market; the impact of competition and the ability of the parties to compete against competitors that may have greater financial and other resources; changes in the business plans of either company; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2001. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements. For Cambridge Antibody Technology Group: Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995: This press release contains statements about Cambridge Antibody Technology Group plc ("CAT") that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward looking statements are based on numerous assumptions regarding CAT's present and future business strategies and the environment in which CAT will operate in the future. Certain factors that could cause CAT's actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition.